obesity
Phages could be used as a drug delivery system for conditions such as inflammation and obesity.
Positive results from Phase 1 trial of BL-001, an innovative live biotherapeutic product (LBP) designed to replicate the metabolic effects of the ketogenic diet.
The discussion with Professor Alessio Fasano highlights the complex interplay between homeostatic, hedonic, and microbiota-driven mechanisms in regulating hunger.
The findings suggest that the composition of the gut microbiota in early life is not a key factor in obesity risk.
A recent study highlights the role of specific obesogenic microbes suggesting potential interventions through targeted regulation of M. rupellensis and myo-inositol metabolism.
The findings of a recent study suggest that Desulfovibrio can drive cancer progression, paving the way for therapeutic approached that targeting the gut microbiota.
Although a causative relationship between obesity and gut microbes remains unclear, microbiota-based treatments may help to combat obesity.
The findings of a recent study suggest that the microbiota-derived metabolite phenyllactic acid can prevent antibiotic-associated obesity in early life.
Karl Alex Hedin (Technical University of Denmark) talks about the potential role of genetically engineering Saccharomyces boulardii to produce an anti-obesity peptide.
The findings of a recent study suggest that the gut microbiota contributes to improve metabolic health after gastric bypass surgery.
